The age-related macular degeneration market was valued at USD 10.46 Billion in 2024, driven by the rising geriatric population. The market is anticipated to grow at a CAGR of 9.70% during the forecast period of 2025-2034, with values likely to reach USD 26.40 Billion by 2034.
Base Year
Historical Year
Forecast Year
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The age-related macular degeneration (AMD) is a disease in which the macula of the eye’s small central region of the retina deteriorates. The macula is considered to be an essential component of the retina, as it regulates the visual perception of the eye. The ability of an individual to read, identify and recognize objects that require immaculate visual details determine macular health.
Usually, after the age of sixty, there is an onset of an eye disease that can gradually destroy the macula, the middle part of the retina, further impairing the central vision of the eye. Age-related macular degeneration (AMD) causes rare blindness as it affects the centre of the eye. The age-related macular degeneration (AMD) industry can be divided based on segments such as product, drug, route of administration, and region.
The industry can be broadly categorised on the basis of product into:
The industry can be divided based on the drug into:
The industry can be divided on the basis of route of administration into:
Looks into the regional markets of age-related macular degeneration (AMD) like:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
The enhanced reimbursement incentives for age-related macular degeneration (AMD) drugs add to the development of the industry. In addition, the age-related macular degeneration market is driven by an increase in the incidence of eye-related disorders and growth in the global geriatric population. Although the growing use of off-label medications and the availability of off-label treatments hinder the industry growth, the rising market trends, such as the advancement of gene therapy for age-related macular degeneration, will result in the growth of the medical therapy of age-related macular degeneration.
Just a few licensed drugs are available for the treatment of the disorder in the market. The related side-effects are also severe to the consumer’s health. Therefore, the need for safe and innovative drugs to treat age-related macular degeneration remains substantially unmet. This has culminated in several drug firms focusing on gene therapy to treat the disease. Intravitreal injection administered gene therapy does not affect the cells. It also protects and enhances the vision of patients. Such advantages will drive demand for gene therapy, which during the forecast period, will have a positive impact on the industry growth globally.
The report presents a detailed analysis of the following key players in the global age-related macular degeneration (AMD) market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:
The EMR report gives an in-depth insight into the industry by providing a SWOT analysis as well as an analysis of Porter’s Five Forces model.
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market was valued at USD 10.46 Billion in 2024.
The market is anticipated to grow at a CAGR of 9.70% during the forecast period of 2025-2034, with the values likely to reach USD 26.40 Billion by 2034.
The market is estimated to witness a moderate growth in the forecast period of 2025-2034 to reach about USD 4.40 billion by 2034.
The major drivers of the industry, such as the enhanced reimbursement policies, increasing prevalence of eye-related disorders amongst the geriatric population, increasing demand for enhanced healthcare facilities, and the growing technological advancements, are expected to aid the market growth.
The key market trends guiding the growth of the age-related macular degeneration (AMD) industry include the growing preference for intravitreal injection administered gene therapy and increasing clinical trials.
The major regions in the industry are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.
Wet AMD and dry AMD are the leading products of age-related macular degeneration (AMD) in the industry.
The major drug segments in the industry include Lucentis, Eylea, and Avastin, among others.
The significant routes of administration available in the industry include intravenous and intravitreal.
The major players in the industry are Bayer AG, F. Hoffmann-La Roche Ltd., Novartis AG, and Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), among others.
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2024 |
| Historical Period | 2018-2024 |
| Forecast Period | 2025-2034 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment
|
| Breakup by Product |
|
| Breakup by Drug |
|
| Breakup by Route of Administration |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
| Report Price and Purchase Option | Explore our purchase options that are best suited to your resources and industry needs. |
| Delivery Format | Delivered as an attached PDF and Excel through email, with an option of receiving an editable PPT, according to the purchase option. |
Datasheet
One User
USD 3,299
USD 2,969
tax inclusive*
Single User License
One User
USD 5,499
USD 4,949
tax inclusive*
Five User License
Five User
USD 6,999
USD 5,949
tax inclusive*
Corporate License
Unlimited Users
USD 8,199
USD 6,969
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-723-689-1189
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share